spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  QLT USA 

 HSMN NewsFeed - 15 Jun 2009
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 26 Aug 2008
QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 28 Mar 2008
Positive results from Visudyne(R) combination therapy study reported at Annual Macula Society Conference
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 17 Mar 2008
QLT announces positive FDA action on Aczone(TM)
Biopharmaceuticals
 HSMN NewsFeed - 18 Jan 2008
QLT reduces workforce as first step in its strategic restructure
Biopharmaceuticals
 HSMN NewsFeed - 18 Oct 2007
QLT Completes Acquisition of ForSight Newco II, Inc.
Biopharmaceuticals Ophthalmology Drug Delivery
 HSMN NewsFeed - 9 Oct 2007
QLT acquires leading edge ocular drug delivery system from ForSight Labs
Biopharmaceuticals Ophthalmology Drug Delivery
 HSMN NewsFeed - 31 Aug 2007
Eligard(R) six-month formulation successfully completes European approval procedure
Biopharmaceuticals Drug Delivery Regulatory Oncology
 HSMN NewsFeed - 23 Jul 2007
QLT announces FDA filing and review of Aczone(TM) labeling supplement for removal of blood screening requirement
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 29 May 2007
QLT USA, Inc. files Aczone(TM) labeling supplement for removal of blood screening requirement
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 1 May 2007
QLT strengthens its expertise in ocular by adding David A. Saperstein M.D. as interim Chief Medical Officer and Paul L. Kaufman M.D. as Head of the Ocular Scientific Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Apr 2007
QLT announces that CHMP will recommend to the European Commission that occult indication be deleted from the Visudyne(R)label in European Union
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 23 Apr 2007
CollaGenex Pharmaceuticals Provides Update on Examination of Incyclinide Patent Application
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 5 Mar 2007
QLT Settles MEEI Lawsuit With Respect to the '303 Patent
Biopharmaceuticals Ophthalmology Litigation
 HSMN NewsFeed - 20 Dec 2006
CollaGenex Pharmaceuticals Signs License and Supply Agreement with MediGene for Marketing Rights to Oracea in EU and Certain Other Countries
Biopharmaceuticals Dermatology Licensing
 HSMN NewsFeed - 1 Dec 2006
Eligard(R) six-month formulation approved in Germany
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 May 2006
CollaGenex Pharmaceuticals Receives FDA Approval for Oracea(TM)
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 25 May 2006
QLT strengthens corporate development and legal functions with the appointment of Peter J. O'Callaghan as Senior Vice President, Corporate Development and General Counsel
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 23

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 23 additional stories matching:
QLT USA
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.